PR55, a Regulatory Subunit of PP2A, Specifically Regulates PP2A-mediated β-Catenin Dephosphorylation[⊡]

Received for publication, April 27, 2009, and in revised form, June 24, 2009 Published, JBC Papers in Press, June 25, 2009, DOI 10.1074/jbc.M109.013698

 $\bm{\mathsf{W}}$ en Zhang $^{\dag\dag}$, Jun Yang $^{\mathsf{S}^{\dag}}$, Yajuan Liu $^{\ddag}$, Xi Chen $^{\dag}$, Tianxin Yu $^{\mathsf{S}}$, Jianhang Jia $^{\dag 2}$, and Chunming Liu $^{\dag \mathsf{S}^{\dag}}$

From the § *Department of Biochemistry and Molecular Biology,University of Texas Medical Branch, Galveston, Texas 77555 and the* ‡ *Department of Molecular and Cellular Biochemistry, Markey Cancer Center, University of Kentucky, Lexington, Kentucky 40506*

A central question in Wnt signaling is the regulation of -**-catenin phosphorylation and degradation. Multiple kinases, including CKIα and GSK3, are involved in β-catenin phosphorylation. Protein phosphatases such as PP2A and PP1** have been implicated in the regulation of β -catenin. However, **which phosphatase dephosphorylates** -**-catenin** *in vivo* **and how** the specificity of β -catenin dephosphorylation is regulated are not clear. In this study, we show that PP2A regulates β -catenin **phosphorylation and degradation** *in vivo***. We demonstrate that** PP2A is required for Wnt/ β -catenin signaling in *Drosophila*. Moreover, we have identified $PR55\alpha$ as the regulatory subunit of PP2A that controls β -catenin phosphorylation and degrada**tion. PR55, but not the catalytic subunit, PP2Ac, directly inter**acts with β -catenin. RNA interference knockdown of PR55 α **elevates β-catenin phosphorylation and decreases Wnt signaling, whereas overexpressing PR55 enhances Wnt signaling.** Taken together, our results suggest that $PR55\alpha$ specifically reg**ulates PP2A-mediated β-catenin dephosphorylation and plays an essential role in Wnt signaling.**

 Wnt/β -catenin signaling plays essential roles in development and tumorigenesis (1–3). Our previous work found that β -catenin is sequentially phosphorylated by CKI α^4 and GSK3 (4), which creates a binding site for β -Trcp (5), leading to degradation via the ubiquitination/proteasome machinery (3). Mutations in β -catenin or APC genes that prevent β -catenin phosphorylation or ubiquitination/degradation lead ultimately to cancer (1, 2).

In addition to the involvement of kinases, protein phosphatases, such as PP1, PP2A, and PP2C, are also implicated in Wnt/ β -catenin regulation. PP2C and PP1 may regulate dephosphorylation of Axin and play positive roles in Wnt signaling (6, 7). PP2A is a multisubunit enzyme (8–10); it has been reported to play either positive or negative roles in Wnt signaling likely by targeting different components (11–21). Toward the goal of understanding the mechanism of β -catenin phosphorylation, we carried out siRNA screening targeting several major phosphatases, in which we found that PP2A dephosphorylates β -catenin. This is consistent with a recent study where PP2A is shown to dephosphorylate β -catenin in a cell-free system (18).

PP2A consists of a catalytic subunit (PP2Ac), a structure subunit (PR65/A), and variable regulatory B subunits (PR/B, PR/B', PR/B", or PR/B""). The substrate specificity of PP2A is thought to be determined by its B subunit (9). By siRNA screening, we further identified that PR55 α , a regulatory subunit of PP2A, specifically regulates β -catenin phosphorylation and degradation. Mechanistically, we found that PR55 α directly interacts with β -catenin and regulates PP2A-mediated β -catenin dephosphorylation in Wnt signaling.

EXPERIMENTAL PROCEDURES

Plasmids-Myc-tagged PR55a was cloned into CS2+MT vector. FLAG-tagged PP2Ac was cloned into pRK5 vector. β -Catenin and Axin constructs have been described previously (4). PR55 α shRNA constructs were purchased from Sigma. The sequences of shRNA oligos targeting the *PR55* gene are: CCG-GAGAAACACAAAGCGAGACATACTCGAGTATGTCTC-GCTTTGTGTTTCTTTTTT (TRCN0000002489), CCGGG-ATCCCAGTAACAGGTCATTTCTCGAGAAATGACCTG-TTACTGGGATCTTTTT (TRCN0000002490), CCGGTC-CTGCTTAGTTGAGATAGTTCTCGAGAACTATCTCAA-CTAAGCAGGATTTTT (TRCN0000002491), CCGGGTAG-ATGATGATGTAGCAGAACTCGAGTTCTGCTACATCAT-CATCTACTTTTT (TRCN0000002492), and CCGGGCAAGT-GGCAAGCGAAAGAAACTCGAGTTTCTTTCGCTTGCCA-CTTGCTTTTT (TRCN0000002493). Clone TRCN0000002493 was used in this study [\(supplemental Fig. S3\)](http://www.jbc.org/cgi/content/full/M109.013698/DC1). The control shRNA sequence is: CCTAAGGTTAAGTCGCCCTCGCTC-TAGCGAGGGCGACTTAACCTTAGG.

siRNA—siRNAs for *PP1*, *PP5*, and different subunits of *PP2A* were purchased from Qiagen [\(supplemental Fig. S1\)](http://www.jbc.org/cgi/content/full/M109.013698/DC1). The oligonucleotide sequences of these siRNAs are: AACATCGACA-GCATTATCCAA (si02225776 for *PP1*), ATGGAACTTGAC-GATACTCTA (si02225783 for *PP2Ac*), CTCGTGGAAACC-ACACTCAAA (si02225853 for *PP5*), CTGCAGATGATTTG-CGGATTA (si02225825 for *PR55α*), CAGCGTATTCTGAT-ATAGTAA (si02225846 for *PR61α*), GAAGTTGTTTATGG-AAATGAA (si02653812 for *PR61*8), and CCGGTGATATTG-ACAATAGGA (si02659048 for *PR61* ϵ). Negative control siRNA was also purchased from Qiagen (1027281). siRNAs were transfected into HEK293T or SW480 cells at a final con-

[□]**^S** The on-line version of this article (available at http://www.jbc.org) contains [supplemental Figs. S1–S5](http://www.jbc.org/cgi/content/full/M109.013698/DC1).
¹ Both authors contributed equally to this work.

² Supported by National Institutes of Health Grant R01GM079684. ³ Supported by National Institutes of Health Grant R01DK071976 and an

award from the Charlotte Geyer Foundation. To whom correspondence should be addressed: 741 S. Limestone, B375 BBSRB, Lexington, KY 40506.

Fax: 859-257-6030; E-mail: chunming.liu@uky.edu. ⁴ The abbreviations used are: CKI, casein kinase 1; GSK, glycogen synthase kinase; PP2Ac, catalytic subunit of PP2A; siRNA, small interfering RNA; shRNA, short hairpin RNA; HEK, human embryonic kidney; Ab, antibody; GST, glutathione *S*-transferase; OA, okadaic acid; Arm, armadillo; DN, dominant-negative.

centration of 10 nM, using Lipofectamine 2000. Cell lysates were analyzed after 3 days.

Cell Lines—HEK293T and SW480 cells were maintained in Dulbecco's modified Eagle's medium (Hyclone) containing 10% fetal bovine serum (Hyclone), 1% penicillin/streptomycin, and 1% glutamine at 37 °C in 5% CO₂. HEK293 cells were cotransfected with shRNA plasmid, psPAX2 packaging plasmid, and pMD2.G envelope plasmid. Virus-containing media was harvested 48 h after transfection, followed by infection of target HEK293T and SW480 cells. Stabled cells were selected with 2 μ g/ml puromycin 48 h after infection. The stabled cells from a mixed population were used in the experiments.

Immunoprecipitation, Western Blot, and Immunostaining— Cells were lysed in 1% Triton buffer or hypotonic buffer as previously described (22). Immunoprecipitation and Western blot were performed as previously described (4, 23). PP2Ac Ab (2038), PR55 α Ab (2290), and phospho- β -catenin Abs (9561, 9564, 9566, and 9567) were purchased from Cell Signaling Technology. Total β -catenin Ab was purchased from Sigma (c2206). Immunostaining of mammalian cells was performed as described previously (23).

Reporter Assay—Super8xTOPFlash reporter was kindly provided by Dr. Randall Moon, University of Washington. Super8xTOPFlash reporter and *Renilla* reporter were cotransfected into HEK293T cells using the calcium transfection method. Luciferase and *Renilla* activities were analyzed with the Dual-Luciferase® Reporter Assay Kit from Promega.

In Vitro Kinase and in Vitro Phosphatase Assays—Purified GST- β -catenin was phosphorylated by purified GSK3 or CKI α in $1\times$ kinase buffer plus 0.2 mm ATP at 30 °C for 30 min. Phosphorylated β -catenin can also be immunoprecipitated from HCT116 or SW480 cell extracts. Phosphorylated β -catenin was incubated with phosphatase buffer only, or purified PP2A, PP1, or PP5 for 30 min at 37 °C. β -Catenin phosphorylation was analyzed by Western blot with phospho-specific Abs. Purified $CKI\alpha$ and GSK3 have been described (4). PP1 and PP2A were from New England Biolabs (P0754S) and Millipore (14-111), respectively. Recombinant human GST-PP5 was purified from bacteria. PP2A holoenzyme containing PR55 α was purified from HEK293T cells as described below.

Protein Purification—GST fusion proteins have been described in our previous study (4). Histidine-tagged PP2Ac and PR55 α were cloned in pET-28 vector (Novagen) and transformed into BL21(DE3). A single colony was picked up and cultured at 37 °C. Protein expression was induced by 0.4 mm isopropyl 1-thio- β -D-galactopyranoside. Bacteria was pelleted by a microcentrifuge and resuspended in lysis buffer (50 mm NaH_2PO_4 , 300 mm NaCl, 10 mm imidazole, 0.1% Triton 100, pH 8.0) and sonicated on ice for 5×15 s. Cleared lysate was incubated with 100 ml of nickel-nitrilotriacetic acid beads (Qiagen 30210) for 1 h at 4 °C. Beads were washed with 3×1 ml of wash buffer (50 mm NaH_2PO_4 , 300 mm NaCl, 20 mm imidazole, 0.1% Triton 100, pH 8.0). Recombinant protein was eluted by 100 μ l of elution buffer (50 mm NaH_2PO_4 , 300 mm NaCl, 250 mm imidazole, 0.1% of Triton 100, pH 8.0). Protein concentration was determined by a Bio-Rad protein assay kit (500-0006).

PP2A holoenzyme containing $PR55\alpha$ was purified according to the method described by Adams and Wadzinski (24). FLAG-

FIGURE 1. Screening of phosphatases that regulate β -catenin phospho**rylation.** A, HEK293T cells were treated with 1 nm tautomycine (TM), 10 nm okadaic acid (OA), and dimethyl sulfoxide (*Control*), respectively. Cytoplasmic fractions were isolated and analyzed by Western blot using Abs that recognize total β-catenin or GSK3-phosphorylated β-catenin (p-S33, S37, T41). *B*, SW480 cells were treated with 25 mM LiCl for 0, 15, and 30 min. Cell lysates were analyzed by Western blot using Abs that recognize total β -catenin or phosphorylated β -catenin. C, SW480 cell were transfected with control siRNA and siRNAs for the PP1, PP5, and the catalytic subunit of PP2A (*PP2Ac*). Cell lysates were analyzed by Western blot using Abs that recognize total β -catenin, CKIα-phosphorylated β-catenin (p-S45), or GSK3-phosphorylated β-catenin. *D*, phosphorylated β -catenin was immunoprecipitated from HCT116 cells. Equal amounts of β -catenin were incubated with purified PP1 (0.5 and 2 units), PP2A (0.5 unit), and PP5 for 30 min. Phosphatase buffer alone was used as a control. β -Catenin dephosphorylation was analyzed by Western blot using Abs that recognize total β -catenin or phosphorylated β -catenin.

tagged PR55 α was transcribed into HEK293T cells. PP2A holoenzyme was immunoprecipitated with FLAG-conjugated beads and eluted by FLAG peptides.

Drosophila Stocks and Immunostaining of Wing Discs— *MS1096*, *actCD2gal4*, *ptc*-*gal4*, *UAS-DN-mts*, *UAS-mts-RNAi*, *UAS-mts* has been described (25, 26). Standard protocols for immunofluorescence staining were used. Wing imaginal discs from late third instar larvae were immunostained with mouse anti-Arm (Developmental Studies Hybridoma Bank), rabbit anti-Dll (Dr. Sean Carroll), and goat anti-Sen (Dr. Hugo Bellen) Abs.

RESULTS

PP2A Regulates β-Catenin Dephosphorylation—Our previous study (4) showed that the N terminus of β -catenin is phosphorylated by CKI α and GSK3. We further showed that Wnt inhibits GSK3 activity, resulting in a dramatic decrease of β -catenin phosphorylation and increase of stabilization (4). Because protein kinases and phosphatases often have opposing actions, to investigate whether phosphatases are involved in β -catenin dephosphorylation, and if so which phosphatases are responsible, we treated HEK293T cells with 1 nm tautomycin and 10 nm okadaic acid (OA), which preferentially inhibits PP1 and PP2A, respectively. We found that the abundance of phosphorylated β -catenin is elevated by OA but not tautomycin, suggesting that PP2A may regulate β -catenin phosphorylation (Fig. 1*A*, *top panel*).

To determine which phosphatase is responsible for β -catenin dephosphorylation, we decided to use siRNA to knockdown each of these phosphatases. However, phosphorylated β -cate-

nin is rapidly degraded in HEK293T cells. Thus, it is difficult to analyze β -catenin phosphorylation in these cells. Recently, we noted that β -catenin degradation but not phosphorylation is inhibited in the colon cancer cell line SW480 (22). When SW480 cells were treated with LiCl, which inhibits GSK3 activity, the levels of phosphorylated β -catenin were significantly decreased (Fig. $1B$, *top panel*). Because β -catenin degradation is blocked in SW480 cells, we reasoned that the decrease in β -catenin phosphorylation is caused by phosphatase activity but not protein turnover. SW480 cells provide a good model to analyze β -catenin phosphorylation without the interference of β -catenin degradation.

To identify the phosphatase that specifically dephosphorylates β -catenin, we performed siRNA screening in SW480 cells. PP1, PP5, and the catalytic subunit of PP2A (PP2Ac) were knocked down by siRNAs [\(supplemental Fig. S1,](http://www.jbc.org/cgi/content/full/M109.013698/DC1) *A*–*C*). The levels of both CKI α - and GSK3-phosphorylated β -catenin were significantly increased in the PP2Ac-depleted cells (Fig. 1*C*, *top* and *middle panels*). Total levels of β -catenin were not changed in SW480 cells (Fig. 1*C*, *bottom panel*). These data confirmed that PP2A is required for β -catenin dephosphorylation. To determine whether PP2A can directly dephosphorylate β -catenin, phosphorylated β -catenin was immunoprecipitated from HCT116 cells and incubated with purified PP1, PP5, and PP2A holoenzyme. PP2A efficiently dephosphorylated β -catenin within 30 min (Fig. 1*D*). PP2A can dephosphorylate *in vitro* phosphorylated $GST-\beta$ -catenin as well (not shown).

PP2A Is Essential for Wingless Signaling by Regulating Armadillo Levels in Drosophila—Our results and the results from a phosphatase reconstitution study (18) suggest that PP2A could dephosphorylate and stabilize β -catenin, thus playing positive roles in Wnt signaling. However, the *in vivo* functions of PP2A in Wnt signaling remain elusive likely due to multiple roles of PP2A in the Wnt signaling cascade. To define PP2A functions *in vivo*, we turned to the *Drosophila* wing development where Wingless (Wg), a member of the Wnt gene family, exerts a highly conserved biological influence through the canonical Wnt/ β -catenin pathway. We examined the levels of β -catenin homolog Armadillo (Arm) and the expression of Wg target genes in *Drosophila*. We found that expressing dominant-negative PP2Ac, DN-Mts in *Drosophila*, by the wing-specific *MS1096 gal4*, caused significant reduction of Arm levels (Fig. 2*B*, compared with wild-type Arm staining in Fig. 2*A*) and severe suppression of Wg target genes such as *distalless* (*dll*) and *senseless* (*sen*) (compare Fig. 2, *B'*, *B*" with *A'*, *A*"). Consistently, we found that *mts* RNAi blocked Arm accumulation (Fig. 2*C*), thus the attenuated Dll expression (Fig. 2*D*) in *Drosophila* wing discs. We also performed a gain-of-function study by using the *ptc*-*gal4* that drives gene expression in a stripe anteriorally to the anterior/posterior boundary of the wing disc (26). We found that expressing *UAS-mts* by *ptc-gal4* elevated Arm levels (Fig. 2*E*).

Identification of PR55- *as the Regulatory B Subunit That Controls -Catenin Phosphorylation*—PP2A holoenzyme comprises a catalytic C subunit, a scaffolding A subunit, and a regulatory B subunit, which controls substrate specificity $(8-10)$. There are more than 20 regulatory B subunits in the human genome (9).We hypothesize that PP2A plays different roles and

PR55 α **Regulates β-Catenin Dephosphorylation**

FIGURE 2. **PP2A is essential for***Drosophila* **Wg signaling.** *A*, *A*, and *A*-, a wildtype wing disc was stained with anti-Arm, Dll, and Sen. *B*, *B'*, and *B"*, UAS-DN-mts was expressed by *MS1096 gal4* and immunostained for Arm, Dll, and Sen. *C* and *C*, *UAS-MtsRNAi* was expressed by *actCD2gal4* and larvae were grown at 20 °C, limiting the strength of *mts* RNAi that could cause cell lethality. Mts knockdown cells were marked by green fluorescent protein expression. *D* and *D*, a wing disc expressing*UAS-mts*RNAi was immunostainedfor Arm and Dll.*Arrow*in *D* indicates the destabilization of Arm and the *arrow* in *D'* indicates the downregulatedDll expression by*mts*RNAi. *E* and*E*, a wing disc expressing*UAS-mts*by *ptc*-*gal4* was immunostained with anti-Arm and Sen. *Arrow* in *E* indicates the elevation of Arm by the overexpression of Mts.

regulates multiple steps in the Wnt pathway through distinct regulatory B subunits. Our *in vitro* and *in vivo* studies suggest that PP2A regulates β -catenin phosphorylation. The regulatory B subunit that controls β -catenin dephosphorylation remains to be identified.

We performed another siRNA screening in SW480 cells using siRNAs targeting individual regulatory subunits of PP2A [\(supplemental Fig. S1,](http://www.jbc.org/cgi/content/full/M109.013698/DC1) *D*–*G*). As a control, *PP2Ac* siRNA increased the levels of phosphorylated β -catenin (compare *lane 2* with *lane 1*, Fig. 3*A*, *top panel*). In addition, we found that depletion of PR55 α (also called B55 α) significantly increased the levels of phosphorylated β -catenin (Fig. 3A). The levels of phosphorylated β -catenin were not increased by siRNAs targeting other PP2A regulatory subunits, such as PR61 α (B56 α), PR61 δ (B56 δ), and PR61 ϵ (B56 ϵ), although these subunits were implicated in Wnt signaling as well (15, 17, 20).

PR55 α comprises a seven-bladed β -propeller, or WD40 repeats (27). Each blade comprises four antiparallel β -strands. These domains are involved in protein-protein interactions. To analyze the binding between PR55 α and PP2Ac, Myc-tagged

FIGURE 3. Identification of PR55 α as the regulatory B subunit that controls β-catenin phosphorylation. A, SW480 cells were transfected with siRNAs targeting several different regulatory subunits of PP2A. Negative control siRNA and $PP2Ac$ siRNA were used as controls. Total β -catenin and phosphorylated β -catenin were analyzed by Western blot with anti-Ser(P)-45 and anti- β -catenin Abs. *B*, interaction between PR55 α and PP2Ac. Myc-tagged $PR55\alpha$ was cotransfected with CS2 control plasmid or FLAG-tagged PP2Ac into HEK293T cells. PR55 α protein was immunoprecipitated from cell lysates with an anti-Myc Ab. The presence of PP2Ac in the immunoprecipitated (*IP*) samples was analyzed by Western blot with an anti-FLAG Ab. The levels of $PP2Ac$ and $PR55\alpha$ in the cell lysates were analyzed as control. *C*, SW480 cells were infected with lentiviruses that express control shRNA or $PR55\alpha$ shRNA. Stable cells were selected with puromycin. PR55 α protein levels in these cells were analyzed by Western blot with an anti-PR55 α Ab. Total β -catenin and phosphorylated β -catenin were analyzed with an anti- β -catenin Ab and phospho-specific Abs that recognize different phosphorylation sites of B-catenin. *D*, SW480 cells were treated with dimethyl sulfoxide or 10 nm OA. Total β -catenin and phosphorylated β -catenin were analyzed with an anti- β catenin Ab and phospho-specific Abs against β -catenin.

PR55 and FLAG-tagged PP2Ac were co-transfected into HEK293T cells. As expected, PR55 α forms a complex with PP2Ac (Fig. 3*B*). To confirm the siRNA results and further analyze the PR55 α function, we generated stable SW480 cells that express PR55α shRNA (Fig. 3C and [supplemental Fig. S3\)](http://www.jbc.org/cgi/content/full/M109.013698/DC1). $PR55\alpha$ was efficiently knocked down in these cells compared with the SW480 cells with control shRNA (Fig. 3*C*, *top panel*). Consistent with the siRNA result in Fig. 3*A*, the levels of both $CKI\alpha$ and GSK3-phosphorylated β -catenin were increased in SW480 cells expressing PR55α shRNA (Fig. 3C, *second* and *third panels*), with the total amount of β -catenin unchanged (Fig. 3*C*, *bottom panel*).

Although CKI α and GSK3 phosphorylate the N terminus of β -catenin and control β -catenin degradation, other kinases can also phosphorylate β -catenin. It has been shown that AKT and PKA phosphorylated β -catenin at Ser-552 and Ser-675, which regulate the activation and nuclear translocation of β -catenin $(28-30)$. When SW480 cells were treated with 10 nm OA, the levels of Ser-552 and Ser-675-phosphorylated β -catenin were also increased (Fig. 3*D*, *second* and *third panels*), suggesting that these sites are also regulated by protein phosphatase. Interestingly, we found that depletion of $PR55\alpha$ in SW480 cells increased the abundance of β -catenin with Ser-552 and Ser-675 phosphorylation (Fig. 3*C*, *fourth* and *fifth panels*), suggesting that PP2A/PR55 α may affect the phosphorylation of Ser-552 and Ser-675 thus the activation and nuclear translocation of β -catenin.

PR55α Interacts with β-Catenin in Mammalian Cells—We analyzed the localization of PR55 α in SW480 cells. PR55 α was localized in both the cytoplasm and nucleus (Fig. 4*A*). As a control, β -catenin localized on the membrane and in the cytoplasm and significantly accumulated in the nucleus (Fig. 4*A*). To test if PR55 α interacts with β-catenin, endogenous PR55 α protein was immunoprecipitated from SW480 cells, and the presence of β -catenin was analyzed by Western blot. We found that β -catenin indeed binds PR55 α (Fig. 4*B*). Although several phosphatases and their subunits are involved in Wnt signaling, PR55 α is the first phosphatase subunit found to bind β -catenin. To analyze which domains of β -catenin bind PR55 α , we generated several β -catenin deletions (Fig. 4*C*). Full-length β -catenin strongly bound PR55 α (Fig. 4D). The C terminus containing armadillo repeats 11–12, or the N terminus containing armadillo repeats 1–10, bound PR55 α weakly, whereas the N terminus with no armadillo repeat did not bind PR55 α , suggesting that PR55 α may bind multiple armadillo repeats of β -catenin (Fig. 4*D*).

 $PR55\alpha$ has 7 WD40 repeats. To test which WD40 repeats bind β-catenin, we generated a panel of PR55 α deletions (Fig. 4*E*). Using the immunoprecipitation assay, we found that β-catenin binds multiple domains of PR55α (Fig. 4*F*). This is consistent with the result that multiple armadillo repeats of β-catenin bind PR55α (Fig. 4D).

*PR55α Directly Binds Both β-Catenin and Axin—*It has been reported that PP2Ac interacts with Axin (14). To test if PR55 α binds Axin as well, Myc-tagged PR55 α and FLAG-tagged Axin or β -catenin were cotransfected into HEK293T cells. Using an immunoprecipitation assay, we found that PR55 α not only interacts with β -catenin, but also strongly interacts with Axin (Fig. 5*A*, lane 2, top panel). Our data indicate that PR55α falls into the Axin- β -catenin protein complex and further suggests that PR55 α acts as the PP2A regulatory subunit in regulating β -catenin phosphorylation.

Because β -catenin directly binds Axin, PR55 α could bind β -catenin indirectly through Axin. To test this possibility, we purified histidine-tagged PP2Ac and PR55α from *Escherichia coli* BL21(DE3). These proteins were incubated with purified GST, GST- β -catenin, GST-Axin(Cat+S45K), and GST- $Axin(G3+Cat)$ [\(supplemental Fig. S4\)](http://www.jbc.org/cgi/content/full/M109.013698/DC1). GST-Axin(Cat+S45K) interacted with CKI α and GST-Axin(G3+Cat) interacted with GSK3 (Fig. 5*B*, *bottom two panels*), as we reported previously (4). PP2Ac bound GST-Axin(Cat+S45K) (Fig. 5*B*, *top panel*), as previously reported (14). In this study, we found that $PR55\alpha$ binds not only GST-Axin(Cat+S45K) but also GST-Axin(G3+Cat) and GST-β-catenin (Fig. 5*B*, *second panel*, *lane* 4). Neither PP2Ac nor PR55 α binds GST protein. These results suggest that PP2A directly binds Axin, whereas PR55 α directly binds both Axin and β -catenin. PP2A and PR55 α may bind distinct domains of Axin. The binding between Axin(Cat) and

FIGURE 4. **PR55** α **interacts with** β **-catenin.** A, localization of PR55 α in SW480 cells. SW480 cells were stained with Abs against β -catenin (*green*) and PR55 α (*red*). *B*, endogenous PR55 α binds endogenous β -catenin. PR55 α was immunoprecipitated (*IP*) with an anti-PR55 α Ab and β -catenin was analyzed by Western blot with an anti-β-catenin Ab. The endogenous PR55α and β-catenin in the cell lysates were analyzed as control. C, schematic diagram of β-catenin deletion ϵ onstructs. The *black boxes* are armadillo repeats. D, armadillo domains of β -catenin bind PR55 α . HEK293T cells were cotransfected with Myc-tagged PR55 α and Myc-tagged β -catenin or its mutants. PR55 α was immunoprecipitated with an anti-PR55 α Ab. β -Catenin proteins were analyzed by Western blot with an anti-Myc Ab. The expression of these proteins was analyzed by Western blot with an anti-Myc Ab. E, schematic diagram of PR55 α deletion constructs. The hexagons are WD40 repeats. F, β-catenin interacts with multiple domains of PR55α. HEK293T cells were cotransfected with FLAG-tagged β-catenin and Myc-tagged PR55 α or its mutants. PR55 α proteins were immunoprecipitated with 9E10-conjugated beads and β -catenin was analyzed by Western blot with an anti-FLAG Ab. The levels of PR55 α and β -catenin proteins in the cell lysates were analyzed as control.

PR55 α was tested [\(supplemental Fig. S5\)](http://www.jbc.org/cgi/content/full/M109.013698/DC1). We found that the $Axi(Cat)$ fragment is not sufficient for PR55 α binding.

To test which WD40 repeats of PR55 α bind Axin, we analyzed the binding between Axin and PR55 α mutants (Fig. 4*C*). Using the immunoprecipitation assay, we found that unlike β -catenin, Axin only binds the PR55 α fragments containing the last 3– 4 WD40 repeats (Fig. 5*C*). To understand the function of PR55 α in Wnt signaling, we performed a reporter assay in HEK293T cells using Super8xTOPFlash.

PR55 α alone has no significant effect on the reporter activity (not shown). However, when $PR55\alpha$ was cotransfected with Wnt3A, it synergized with Wnt3A and significantly increased the reporter activity (Fig. 5D). PR55 α mutants PR55 $\alpha\Delta$ 2 and PR55 $\alpha\Delta$ 3 have less effect, whereas PR55 $\alpha\Delta$ 1 has no effect on the reporter activity; this is consistent with their binding affinities to β -catenin and Axin. These results further suggest that PR55 α plays a positive role in Wnt signaling.

FIGURE 5. $\mathsf{PR55}_\alpha$ directly interacts with β -catenin and Axin and regulates PP2A-mediated β -catenin **dephosphorylation.** A, PR55α interacts with both Axin and β-catenin. HEK293T cells were cotransfected with Myc-tagged PR55 α and FLAG-tagged Axin, or FLAG-tagged β -catenin. Axin and β -catenin were immunoprecipitated from the cell lysates using an anti-FLAG Ab. The presence of PR55 α in the immunoprecipitated samples were analyzed with an anti-Myc Ab. The protein levels of Axin and β -catenin were analyzed with an anti-FLAG Ab. *B*, PR55 α directly interacts with β -catenin and Axin. Purified histidine-tagged PP2Ac and PR55 α were incubated with purified GST, GST-β-catenin, GST-Axin(Cat+S45K), and GST-Axin(G3+Cat), respectively. These GST-Axin fusion proteins have been described previously (4). GST fusion proteins were pulled down with glutathione-agarose beads. PP2Ac and PR55 α were analyzed with anti-PP2Ac and anti-PR55 α Abs. The binding between these GST proteins and CKI α and GSK3 were analyzed as controls. C , the C-terminal region of PR55 α interacts with Axin. HEK293T cells were cotransfected with FLAG-tagged Axin and Myc-tagged PR55 α or its mutants. PR55 α proteins were immunoprecipitated with 9E10-conjugated beads and Axin was analyzed by Western blot with an anti-FLAG Ab. The levels of PR55 α and Axin proteins in the cell lysates were analyzed as control. D, PR55 α enhances Wnt signaling. Super8XTOPFlash was cotransfected with Wnt3A plus CS2 or Wnt3A plus PR55 α constructs into HEK293T cells. Luciferase activity was analyzed and normalized. *E*, PR55 α regulates -catenin stability. *Left panel*, HEK293T cells were infected with lentiviruses that express control shRNA or ι PR55 α shRNA. Stable cells were selected with puromycin. Cytoplasmic PR55 α and β -catenin protein levels were analyzed by Western blot with anti-PR55 α and anti- β -catenin Abs. *Right panel*, the HEK293T cell line contains P R55 α shRNA (HEK293i) and the control HEK293T cell line were treated with control conditioned medium or Wnt3A-conditioned medium for 6 h. Cytoplasmic fractions were isolated from these cells. β -Catenin and PR55 α levels were analyzed by Western blot using anti- β -catenin and anti-PR55 α Ab. β -Tubulin was analyzed as a loading control. F, PP2A holoenzyme containing PR55 α directly dephosphorylates β -catenin. GST- β -catenin was phosphorylated by CKI and GSK3 *in vitro. Left panel*, Myc-tagged PR55α and FLAG-tagged PP2Ac were cotransfected into HEK293T cells. HEK293T cells transfected with empty vector were used as control. The PR55 α -PP2Ac complex was immunoprecipitated with 9E10-conjugated beads. The beads were resuspended in 1 \times phosphatase buffer and incubated with phosphorylated GST- β -catenin for 30 min. PR55 α , PP2Ac, total $β$ -catenin, and phosphorylated *β*-catenin were analyzed by Western blot. *Right panel*, PP2A holoenzyme containing FLAG-tagged PR55 α was purified from HEK293T cells and incubated with phosphorylated β -catenin for 0, 10, 20, and 30 min. PR55 α and the catalytic subunit of PP2A (*PP2Ac*) were analyzed by Western blot with anti-PR55 α and anti-PP2Ac Abs. β -Catenin was analyzed by Western blot with Abs against phosphorylated β -catenin or total β -catenin.

PP2A/PR55α Regulates β-Catenin Degradation by Directly *Dephosphorylating* β-Catenin-To determine the function of endogenous PR55 α on β -catenin degradation, we generated a stable HEK293T cell line that expresses PR55α shRNA. Cytoplasmic fractions were isolated from this cell line (HEK293i) and the control cell line (HEK293c). PR55 α protein levels were significantly reduced by shRNA (Fig. 5*E*, *left*, *top panel*). PR55 depletion resulted in β-catenin degradation (Fig. 5*E*, *left*, *mid* d le panel). As a loading control, β -tubulin levels were not affected by PR55α shRNA (Fig. 5*E*, *left*, *bottom panel*). It is worth noting that PP2Ac depletion has similar results (14), sug-

gesting that PR55 α and PP2Ac work together in β -catenin regulation. These cells were treated with either control medium or Wnt3A-conditioned medium. Besides the above observations, we found that Wnt3A treatment increased the cytoplasmic levels of β -catenin more efficiently in HEK293c cells than that of the HEK293i cells (Fig. 5*E*, *right*, *middle panel*, *lane 2*, compared with *lane 4*), suggesting that $PR55\alpha$ enhances Wnt-regulated β -catenin stabilization by regulating β -catenin dephosphorylation.

As described above (Fig. 5, *A* and *B*), both PR55 α and PP2Ac bind Axin. Because Axin regulates β catenin phosphorylation, it is also possible that PR55 α indirectly regulates β -catenin phosphorylation by regulating Axin. We have shown that β -catenin can be dephosphorylated by a commercial PP2A holoenzyme (Fig. 1*D*), but it is not clear which regulatory B subunit is presented. To test whether PR55 α directly regulates β -catenin dephosphorylation, Myc-tagged PR55 α and FLAG-tagged PP2Ac were cotransfected into HEK293T cells. The $PR55\alpha$ -PP2A complex was immunoprecipitated with FLAG-conjugated beads and incubated with phosphorylated β -catenin (Fig. 5*F*, left panel). Both CKIa and GSK3 phosphorylations of β -catenin were decreased upon incubation with $PR55\alpha/PP2A$, whereas total β -catenin levels remain unchanged (Fig. 5*F*, *left panel*), suggesting that the $PR55\alpha$ -PP2Ac complex can dephosphorylate β -catenin. To test if PR55 α can recruit endogenous PP2A complex for β -catenin dephosphorylation, we purified PP2A holoenzyme containing $PR55\alpha$ with FLAG-con-

jugated beads, and the holoenzyme was eluted from the beads with FLAG peptides. We demonstrated that the purified PP2A holoenzyme contains both PR55 α and endogenous PP2Ac, and can directly dephosphorylate β-catenin *in vitro* (Fig. 5*F*, *right panel*).

DISCUSSION

 β -Catenin phosphorylation by protein kinases has been well studied (31). How phosphatase regulates β -catenin is less understood. PP2A has been shown to dephosphorylate β -catenin *in vitro* (18). However, PP2A has been suggested to play

both positive and negative roles in Wnt signaling. Our study demonstrated that PP2A regulates β -catenin phosphorylation both *in vitro* and *in vivo*. The specificity of PP2A in Wnt signaling is regulated by the regulatory B subunit. We demonstrated that PR55 α directly interacts with β -catenin and regulates $PP2A$ -mediated β -catenin dephosphorylation.

PP2A Regulates β-Catenin Dephosphorylation—The PP2A inhibitor, OA, increased the levels of phosphorylated β -catenin in HEK293T cells (Fig. 1A). However, the levels of β -catenin are elevated rather than attenuated by OA treatment (Fig. 1*A*, *bottom panel*). This is probably because OA regulates multiple phosphatases that play different roles in β -catenin phosphorylation and degradation. For example, OA also inhibits PP1 and PP5 when used at higher concentrations. Another possibility is that PP2A may regulate the degradation of phosphorylated β -catenin (32).

Because β -catenin degradation but not phosphorylation is inhibited in colon cancer cell line SW480, the SW480 cell line provides a better model to study β -catenin phosphorylation. The siRNA experiments in SW480 cells suggests that PP2A is essential for β-catenin dephosphorylation. The *in vitro* phosphatase assay further demonstrated that PP2A is both necessary and sufficient for β -catenin dephosphorylation. Within 30 min, only PP2A dephosphorylated β-catenin (Fig. 1D). However, after 2 h of incubation, PP1 can also dephosphorylate β -catenin, and PP5 weakly dephosphorylated β -catenin [\(sup](http://www.jbc.org/cgi/content/full/M109.013698/DC1)[plemental Fig. S2\)](http://www.jbc.org/cgi/content/full/M109.013698/DC1), suggesting that PP1 and PP5 are active, but not as specific as PP2A in β -catenin dephosphorylation. In addition, siRNA results suggest that PP1 and PP5 are not required for β -catenin dephosphorylation.

PP2A Function in Wingless Signaling in Drosophila—To test PP2A function *in vivo*, we analyzed Arm and its target genes in *Drosophila*. Loss-of-function of PP2A resulted in decreased levels of Arm (Fig. 2, *B* and*C*). Overexpression of PP2A resulted in increased levels of Arm (Fig. 2*E*). However, under such conditions, we did not observe changes in Wg target genes expression (Fig. 2*E*; not shown). It could be possible that Arm dephosphorylation by PP2A was not sufficient to activate Arm, or, PP2A has additional role(s) in regulating Arm signaling activity. Our finding that PP2A plays a positive role in Wnt signaling is consistent with a previous study (11). However, PP2A also plays negative roles in other studies probably by regulating different substrates. It is important to further determine how PP2A specificity is regulated in Wnt signaling.

PP2A Regulatory Subunit, PR55α, Regulates β-Catenin Dephosphorylation—We performed siRNA screening for the regulatory B subunits of PP2A. Our result demonstrates that PR55 α is required for β -catenin dephosphorylation and further suggests that PP2A regulates different steps of Wnt signaling through distinct regulatory subunits (Fig. 3*A*). We found that PR55 α also regulates the phosphorylation of β -catenin Ser-552 and Ser-675 (Fig. 3, *C* and *D*). This may be one of the reasons why the elevation of Arm caused by overexpressing Mts did not ectopically activate Wg target genes (Fig. 2E', data not shown). The Ser-675 site is highly conserved among species although the function of this phosphorylation has not yet been demonstrated in *Drosophila* or other *in vivo* models.

PR55α Directly Interacts with β-Catenin and Axin—PR55α but not PP2Ac directly binds β -catenin. PR55 α also binds Axin. The armadillo domains of β -catenin interact with PR55 α . The WD40 repeats of PR55 α may have a redundant function in β -catenin binding (Fig. 4*F*). In contrast, only the last 3–4 WD40 repeats of PR55 α bind Axin (Fig. 5C). Besides the WD40 repeats, PR55 α also contains two α helices, which are localized after the fourth and fifth SW40 repeats (27). These α helices may be involved in Axin binding.

PR55- *Containing PP2A Holoenzyme Dephosphorylated -Catenin*—We purified PP2A holoenzyme with FLAG-tagged PR55α. The *in vitro* dephosphorylation results strongly suggest that PR55 α directly regulates PP2A-mediated β -catenin dephosphorylation (Fig. 5*F*). It will be interesting to determine whether PR55 α also regulates Axin phosphorylation and whether Axin regulates $PR55\alpha/PR2A$ activity in future experiments.

Our mechanistic studies of β -catenin dephosphorylation by $PP2A/PR55\alpha$ are fully consistent with the genetic results of the PR55α mutant in *Drosophila* (11). The *Drosophila* PR55α homolog is encoded by *twins* (*tws*). In the *tws*⁻ wing disc, both Arm and its target genes were down-regulated, suggesting that Twins is required for Arm stabilization (11). We also found that overexpression of Twins increased Arm in the wing disc.⁵

In summary, we provide first and direct evidence that PR55 α regulates the specificity of PP2A-mediated β -catenin dephosphorylation. Our work further suggests that PP2A may perform different roles in Wnt signaling by taking advantage of different regulatory B subunits. These findings are not only important for cell signaling and developmental biology, but also have important implications for cancer biology. It has been reported that PR61 γ (B56 γ) but not PR55 α suppressed human cell transformation (33), suggesting that PP2A regulatory B subunits play distinct roles in tumorigenesis. This may be partially due to their distinct roles in Wnt signaling.

Acknowledgments—We thank Tianyan Gao, Paul Evans, Timothy Hofstra, Xi He, and Mark Evers for suggestions and helpful discussions. We are grateful to Drs. Randall Moon, Xinhua Feng, Sean Carroll, Hugo Bellen, and Amita Sehgal for valuable reagents; Vienna Drosophila RNAi Center for RNAi flies; Developmental Studies Hybridoma Bank for Arm antibody; and Hongge Jia for assistance with Mts overexpression experiment.

REFERENCES

- 1. Clevers, H. (2006) *Cell* **127,** 469–480
- 2. Logan, C. Y., and Nusse, R. (2004) *Annu. Rev. Cell. Dev. Biol.* **20,** 781–810
- 3. Moon, R. T. (2005) *Sci. STKE*. 2005, cm1
- 4. Liu, C., Li, Y., Semenov, M., Han, C., Baeg, G. H., Tan, Y., Zhang, Z., Lin, X., and He, X. (2002) *Cell* **108,** 837–847
- 5. Liu, C., Kato, Y., Zhang, Z., Do, V. M., Yankner, B. A., and He, X. (1999) *Proc. Natl. Acad. Sci. U.S.A.* **96,** 6273–6278
- 6. Strovel, E. T., Wu, D., and Sussman, D. J. (2000) *J. Biol. Chem.* **275,** 2399–2403
- 7. Luo, W., Peterson, A., Garcia, B. A., Coombs, G., Kofahl, B., Heinrich, R., Shabanowitz, J., Hunt, D. F., Yost, H. J., and Virshup, D. M. (2007) *EMBO J.* **26,** 1511–1521

⁵ H. Jia, Y. Liu, and J. Jia, unpublished results.

- 8. Cho, U. S., and Xu, W. (2007) *Nature* **445,** 53–57
- 9. Janssens, V., Longin, S., and Goris, J. (2008) *Trends Biochem. Sci*. **33,** 113–121
- 10. Virshup, D. M. (2000) *Curr. Opin. Cell. Biol.* **12,** 180–185
- 11. Bajpai, R., Makhijani, K., Rao, P. R., and Shashidhara, L. S. (2004) *Development* **131,** 1007–1016
- 12. Creyghton, M. P., Roël, G., Eichhorn, P. J., Hijmans, E. M., Maurer, I., Destrée, O., and Bernards, R. (2005) *Genes Dev.* **19,** 376–386
- 13. Creyghton, M. P., Roël, G., Eichhorn, P. J., Vredeveld, L. C., Destrée, O., and Bernards, R. (2006) *Proc. Natl. Acad. Sci. U.S.A.* **103,** 5397–5402
- 14. Hsu, W., Zeng, L., and Costantini, F. (1999) *J. Biol. Chem.* **274,** 3439–3445
- 15. Li, X., Yost, H. J., Virshup, D. M., and Seeling, J. M. (2001) *EMBO J.* **20,** 4122–4131
- 16. Ratcliffe, M. J., Itoh, K., and Sokol, S. Y. (2000) *J. Biol. Chem.* **275,** 35680–35683
- 17. Seeling, J. M., Miller, J. R., Gil, R., Moon, R. T., White, R., and Virshup, D. M. (1999) *Science* **283,** 2089–2091
- 18. Su, Y., Fu, C., Ishikawa, S., Stella, A., Kojima, M., Shitoh, K., Schreiber, E. M., Day, B. W., and Liu, B. (2008) *Mol. Cell* **32,** 652–661
- 19. Yamamoto, H., Hinoi, T., Michiue, T., Fukui, A., Usui, H., Janssens, V., Van Hoof, C., Goris, J., Asashima, M., and Kikuchi, A. (2001) *J. Biol. Chem.* **276,** 26875–26882
- 20. Yang, J., Wu, J., Tan, C., and Klein, P. S. (2003) *Development* **130,** 5569–5578
- 21. Yokoyama, N., Yin, D., and Malbon, C. C. (2007) *J. Mol. Signal*. **2,** 11
- 22. Yang, J., Zhang, W., Evans, P. M., Chen, X., He, X., and Liu, C. (2006) *J. Biol. Chem.* **281,** 17751–17757
- 23. Zhang, W., Chen, X., Kato, Y., Evans, P. M., Yuan, S., Yang, J., Rychahou, P. G., Yang, V. W., He, X., Evers, B. M., and Liu, C. (2006) *Mol. Cell. Biol.* **26,** 2055–2064
- 24. Adams, D. G., and Wadzinski, B. E. (2007) *Methods Mol. Biol*. **365,** 101–111
- 25. Jia, H., Liu, Y., Yan, W., and Jia, J. (2009) *Development* **136,** 307–316
- 26. Johnson, R. L., Grenier, J. K., and Scott, M. P. (1995) *Development* **121,** 4161–4170
- 27. Xu, Y., Chen, Y., Zhang, P., Jeffrey, P. D., and Shi, Y. (2008) *Mol. Cell* **31,** 873–885
- 28. Fang, D., Hawke, D., Zheng, Y., Xia, Y., Meisenhelder, J., Nika, H., Mills, G. B., Kobayashi, R., Hunter, T., and Lu, Z. (2007) *J. Biol. Chem.* **282,** 11221–11229
- 29. He, X. C., Yin, T., Grindley, J. C., Tian, Q., Sato, T., Tao, W. A., Dirisina, R., Porter-Westpfahl, K. S., Hembree, M., Johnson, T., Wiedemann, L. M., Barrett, T. A., Hood, L., Wu, H., and Li, L. (2007) *Nat. Genet.* **39,** 189–198
- 30. Taurin, S., Sandbo, N., Qin, Y., Browning, D., and Dulin, N. O. (2006) *J. Biol. Chem.* **281,** 9971–9976
- 31. Huang, H., and He, X. (2008) *Curr. Opin. Cell. Biol.* **20,** 119–125
- 32. Xing, Y., Clements, W. K., Le Trong, I., Hinds, T. R., Stenkamp, R., Kimelman, D., and Xu, W. (2004) *Mol. Cell* **15,** 523–533
- 33. Chen, W., Possemato, R., Campbell, K. T., Plattner, C. A., Pallas, D. C., and Hahn, W. C. (2004) *Cancer Cell*. **5,** 127–136

